Denali Capital Postpones Longevity Biomedical Deal Vote

Denali Capital Acquisition announced that its shareholder meeting originally scheduled for Jan. 4 is postponed to Jan. 9 at 9 a.m. Eastern.

As a result of this change, the redemption deadline has been extended to Jan. 5 at 5 p.m..

Longevity in August agreed to waive the deal’s $30 million cash closing condition. The SPAC has secured an $18 million PIPE commitment from FutureTech Capital to support the acquisition.

The target is focused on advancing new technologies across therapeutics, health monitoring and digital health solutions “to increase human health span.”

As announced in January, the deal has a pro forma equity valuation of approximately $236.2 million, which assumes zero redemptions. Read more.

Total
0
Shares
Related Posts